Erector Spinae Plane Block Versus General Anesthesia in Breast Cancer Surgeries
Primary Purpose
Analgesia
Status
Recruiting
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Bilevel erector spinae plane block
Single level erector spinae plane block
Intravenous morphine
Sponsored by

About this trial
This is an interventional treatment trial for Analgesia
Eligibility Criteria
Inclusion Criteria:
- Female
- Diagnosed with breast cancer
Exclusion Criteria:
- Patient refusal
- coagulation defects
- bone metastases
- abnormal kidney and/or liver function tests
Sites / Locations
- Walaa Y ElsabeenyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Active Comparator
Arm Label
Bilevel erector spinae plane block
Single level erector spinae plane block
Intravenous morphine
Arm Description
Bilevel erector spinae block at 3rd and 5th thoracic vertebral levels
single level erector spinae plane block at 5th thoracic vertebral levels
Intravenous morphine 0.1 mg/ kg
Outcomes
Primary Outcome Measures
Total analgesic requisite
total postoperative morphine consumption
Secondary Outcome Measures
Full Information
NCT ID
NCT05429489
First Posted
June 17, 2022
Last Updated
October 15, 2023
Sponsor
National Cancer Institute, Egypt
1. Study Identification
Unique Protocol Identification Number
NCT05429489
Brief Title
Erector Spinae Plane Block Versus General Anesthesia in Breast Cancer Surgeries
Official Title
Comparison of the Efficacy of Bilevel Erector Spinae Plane Block and Single Level Erector Spinae Plane Block Versus General Anesthesia in Breast Cancer Surgeries
Study Type
Interventional
2. Study Status
Record Verification Date
October 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 27, 2022 (Actual)
Primary Completion Date
October 30, 2023 (Anticipated)
Study Completion Date
November 10, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Cancer Institute, Egypt
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
This study aims at comparing the analgesic efficacy and safety of bilevel erector spinae versus single level versus general anesthesia for breast cancer surgeries
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Analgesia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
InvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Bilevel erector spinae plane block
Arm Type
Experimental
Arm Description
Bilevel erector spinae block at 3rd and 5th thoracic vertebral levels
Arm Title
Single level erector spinae plane block
Arm Type
Experimental
Arm Description
single level erector spinae plane block at 5th thoracic vertebral levels
Arm Title
Intravenous morphine
Arm Type
Active Comparator
Arm Description
Intravenous morphine 0.1 mg/ kg
Intervention Type
Procedure
Intervention Name(s)
Bilevel erector spinae plane block
Intervention Description
Bilevel erector spinae plane block at 3rd and 5th thoracic vertebral levels
Intervention Type
Procedure
Intervention Name(s)
Single level erector spinae plane block
Intervention Description
Single level erector spinae plane block at 5th thoracic vertebrae
Intervention Type
Drug
Intervention Name(s)
Intravenous morphine
Intervention Description
Intravenous morphine 0.1 mg/kg
Primary Outcome Measure Information:
Title
Total analgesic requisite
Description
total postoperative morphine consumption
Time Frame
First 24 hours postoperatively
10. Eligibility
Sex
Female
Gender Based
Yes
Gender Eligibility Description
Females
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Female
Diagnosed with breast cancer
Exclusion Criteria:
Patient refusal
coagulation defects
bone metastases
abnormal kidney and/or liver function tests
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Walaa Y Elsabeeny, MD
Phone
+201007798466
Email
walaa.elsabeeny@nci.cu.edu.eg
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Walaa Y Elsabeeny, MD
Organizational Affiliation
National Cancer Institute (NCI)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Walaa Y Elsabeeny
City
Cairo
ZIP/Postal Code
11796
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Walaa Y Elsabeeny, MD
Phone
+201007798466
Email
walaa.elsabeeny@nci.cu.edu.eg
12. IPD Sharing Statement
Learn more about this trial
Erector Spinae Plane Block Versus General Anesthesia in Breast Cancer Surgeries
We'll reach out to this number within 24 hrs